Conjunctival Swab vs Nasopharyngeal Swab in Patients With COVID-19

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04444596

Enrollment

100

Registered

2020-06-23

Start date

2020-06-17

Completion date

2021-03-31

Last updated

2020-06-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19, SARS-CoV 2

Brief summary

The aim of this possible study is to identify if SARS-CoV-2 can be found in the tear film and conjunctiva of a patient with COVID-19.

Interventions

DIAGNOSTIC_TESTConjunctival swab and nasopharyngeal swab

Both conjunctival swab and nasopharyngeal swab for SARS-COV 2 are conducted in patients with COVID-19.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Age ≥ 18 years * A confirmed COVID-19 disease * Signed and dated declaration of consent * The patient fell ill in Tyrol

Exclusion criteria

* none

Design outcomes

Primary

Measure	Time frame	Description
SARS-CoV2 positive conjunctival swabs	1 year	The primary endpoint is the number of conjunctival swabs tested positive for SARS-CoV2.

Secondary

Measure	Time frame	Description
Conjunctival swab vs nasopharyngeal swab	1 year	The secondary target is the difference between the conjunctival swab tested positive for SARS-CoV2 and the nasopharyngeal swab.

Other

Measure	Time frame	Description
Viability of SARS-COV 2	1 year	In the case of a SARS-COV 2 positive conjunctival swab a virus culture will be conducted to clarify, whether it is a viable virus or virus RNA fragments.

Countries

Austria

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026